Selvita is an oncology R&D and drug discovery services company. It operates three business segments: Innovations Platform (internal R&D pipeline), Research Services (medicinal chemistry/biology, biochemistry) and Ardigen (a spin-out bioinformatics company, 52% owned). The lead asset is wholly owned SEL120, currently Phase I-ready after the FDA approved an IND application in March 2019. Selvita is also focusing on its other projects in a broad pipeline dedicated to oncology.
In this video, the company’s chief executive officer Paweł Przewięźlikowski introduces the company and lead assets, and provides an overview of R&D progress and expected news flow.